Ethicon Seeks To Expand Access To Bariatric Surgery, Increase Product Market Share Through Investment
With nearly 30% of the world’s population overweight or obese, Johnson & Johnson's Ethicon division is seeking to expand patients’ access to bariatric surgery in certain countries by funding studies that demonstrate its benefits. By convincing payors in these countries that bariatric surgery addresses not only weight loss but also metabolic diseases, Ethicon hopes to increase its products' market share in these countries, too.
You may also be interested in...
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
Less than a year after signing a major advance purchase agreement to supply its inactivated COVID-19 jab to the EU, Valneva is faced with a termination that could hit its 2022 guidance.
With Switzerland now operating as a third country to the EU, Swiss-based medtech manufacturers are keen to maximize their inherent advantages and build a basis for future growth.